ArticleBMC microbiology2025
Epidemiology and antifungal susceptibilities of rare yeast infections in a tertiary care center.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Captive lizards (Squamata: Sauria) as reservoirs of medically important and antifungal-resistant yeasts.Medical mycology · 2026Article
- Lessons Learned from a Nosocomial Outbreak ofJournal of fungi (Basel, Switzerland) · 2026Article
- Managing Breakthrough Fungal Infections in Hematologic Patients: Determinants and Practical Management from a Latin American Perspective on Behalf of INFOCUS LATAM-ISHAM Working Group.Microorganisms · 2026Review
- BeyondJournal of fungi (Basel, Switzerland) · 2026Article
- Fungal endocarditis complicating intracranial multifocal hemorrhages: a case report.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith advancements in healthcare services, there has been an increase in the population of immunosuppressed patients and the frequency of opportunistic pathogens including rare yeasts (RY). We aimed to provide data on the distribution of RY causing invasive infections and their antifungal susceptibility profiles. In this retrospective study, the distribution of RYs obtained between January 2015 and January 2023 examined. Antifungal susceptibility analyses of the isolates conducted using the broth microdilution method following European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendations. The patients' demographics, predisposing factors and outcomes were investigated.
resultsA total of 15 species were identified from 56 clinical samples, including Clavispora lusitaniae, Kluyveromyces marxianus, Magnusiomyces capitatus, Wickerhamomyces anomalus, Meyerozyma guilliermondii, Magnusiomyces clavatus, Candida dubliniensis, Rhodotorula mucilaginosa, Cyberlindnera jadinii, Pichia inconspicua, Candida auris, Yarrowia lipolytica, Trichosporon asahii, Wickerhamiella pararugosa and Saccharomyces cerevisiae. Observed highly heterogenous antifungal susceptibility results depending on the species. Admission to the intensive care unit (ICU), being 65 years or older, and neutropenia increased mortality. Fourteen-day and 30-day mortality rates were 27.8% and 35.2%, respectively.
conclusionsThe variability of RY encountered in various centers and differences in antifungal susceptibility profiles warrant further research on this topic, both regionally and globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.